(Q43241788)

English

Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants

scientific article published on 16 November 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Cytomegalovirus

0 references

author name string

B George

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

I Kerridge

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

N Gilroy

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

G Huang

4

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

M Hertzberg

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

D Gottlieb

6

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

K Bradstock

7

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

language of work or name

0 references

publication date

16 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

849-855

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

CD8(+) T-cell immunity to cytomegalovirus

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Current understanding of cytomegalovirus infection in immunocompetent individuals

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Distinct patterns of regeneration of central memory, effector memory and effector TCD8+ cell subsets after different hematopoietic cell transplant types: possible influence in the recovery of anti-cytomegalovirus immune response and risk for its rea

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

21 January 2018

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

7 January 2021

based on heuristic

inferred from DOI database lookup

Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

7 January 2021

based on heuristic

inferred from DOI database lookup

Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.273

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2009.273

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43241788&oldid=2205900283"